Inflammatory Mechanisms in Ischemic Cerebrovascular Disease

Neuroinflammation

Volumn , Issue , 2011, Pages 293-324

  Nagai, Mutsumi ^a   Granger, D Neil ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866951063     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384913-7.00014-9     Document Type: Chapter

References (134)

1. Hossmann KA Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994, 36:557-565.
2. Markus R, Reutens DC, Kazui S, Read S, Wright P, Pearce DC, et al. Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival. Brain 2004, 127:1427-1436.
3. Wolburg H, Noell S, Mack A, Wolburg-Buchholz K, Fallier-Becker P Brain endothelial cells and the glio-vascular complex. Cell Tissue Res 2009, 335:75-96.
4. Dirnagl U, Iadecola C, Moskowitz MA Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999, 22:391-397.
5. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis 2008, 25:457-507. European Stroke Organisation (ESO).
6. Sacco RL, Chong JY, Prabhakaran S, Elkind MS Experimental treatments for acute ischaemic stroke. Lancet 2007, 369:331-341.
7. Tanaka R, Komine-Kobayashi M, Mochizuki H, Yamada M, Furuya T, Migita M, et al. Migration of enhanced green fluorescent protein expressing bone marrow-derived microglia/macrophage into the mouse brain following permanent focal ischemia. Neuroscience 2003, 117:531-539.
8. Schilling M, Besselmann M, Leonhard C, Mueller M, Ringelstein EB, Kiefer R Microglial activation precedes and predominates over macrophage infiltration in transient focal cerebral ischemia: a study in green fluorescent protein transgenic bone marrow chimeric mice. Exp Neurol 2003, 183:25-33.
9. Lindsberg PJ, Carpen O, Paetau A, Karjalainen-Lindsberg ML, Kaste M Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation 1996, 94:939-945.
10. Price CJS, Menon DK, Peters AM, Ballinger JR, Barber RW, Balan KK, et al. Cerebral neutrophil recruitment, histology, and outcome in acute ischemic stroke: an imaging-based study. Stroke 2004, 35:1659-1664.
11. Barone FC, Hillegass LM, Tzimas MN, Schmidt DB, Foley JJ, White RF, et al. Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal stroke. Mol Chem Neuropathol 1995, 24:13-30.
12. Dong Y, Benveniste EN Immune function of astrocytes. Glia 2001, 36:180-190.
13. Lucas SM, Rothwell NJ, Gibson RM The role of inflammation in CNS injury and disease. Br J Pharmacol 2006, 147:232-240.
14. Ekdahl CT, Kokaia Z, Lindvall O Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 2009, 158:1021-1029.
15. Yilmaz G, Arumugam TV, Stokes KY, Granger DN Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation 2006, 113:2105-2112.
16. Ishikawa M, Cooper D, Arumugam TV, Zhang JH, Nanda A, Granger DN Platelet-leukocyte-endothelial cell interactions after middle cerebral artery occlusion and reperfusion. J Cereb Blood Flow Metab 2004, 24:907-915.
17. Hayward NJ, Elliott PJ, Sawyer SD, Bronson RT, Bartus RT Lack of evidence for neutrophil participation during infarct formation following focal cerebral ischemia in the rat. Exp Neurol 1996, 139:188-202.
18. Harris AK, Ergul A, Kozak A, Machado LS, Johnson MH, Fagan SC Effect of neutrophil depletion on gelatinase expression, edema formation and hemorrhagic transformation after focal ischemic stroke. BMC Neurosci 2005, 6:49.
19. Arumugam TV, Granger DN, Mattson MP Stroke and T-cells. Neuromolecular Med 2005, 7:229-242.
20. Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S, et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med 2009, 15:192-199.
21. Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I, et al. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med 2009, 15:946-950.
22. Terao S, Yilmaz G, Stokes KY, Russell J, Ishikawa M, Kawase T, et al. Blood cell-derived RANTES mediates cerebral microvascular dysfunction, inflammation, and tissue injury after focal ischemia-reperfusion. Stroke 2008, 39:2560-2570.
23. Liu L, Kubes P Molecular mechanisms of leukocyte recruitment: organ-specific mechanisms of action. Thromb Haemost 2003, 89:213-220.
24. Zhang R, Chopp M, Zhang Z, Jiang N, Powers C The expression of P- and E-selectins in three models of middle cerebral artery occlusion. Brain Res 1998, 785:207-214.
25. Ishikawa M, Cooper D, Russell J, Salter JW, Zhang JH, Nanda A, et al. Molecular determinants of the prothrombogenic and inflammatory phenotype assumed by the postischemic cerebral microcirculation. Stroke 2003, 34:1777-1782.
26. Arumugam TV, Salter JW, Chidlow JH, Ballantyne CM, Kevil CG, Granger DN Contributions of LFA-1 and Mac-1 to brain injury and microvascular dysfunction induced by transient middle cerebral artery occlusion. Am J Physiol Heart Circ Physiol 2004, 287:2555-2560.
27. Ishikawa M, Vowinkel T, Stokes KY, Arumugam TV, Yilmaz G, Nanda A, et al. CD40/CD40 ligand signaling in mouse cerebral microvasculature after focal ischemia/reperfusion. Circulation 2005, 111:1690-1696.
28. Arumugam TV, Chan SL, Jo D, Yilmaz G, Tang S, Cheng A Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Nat Med 2006, 12:621-623.
29. Yenari MA, Sun GH, Kunis DM, Onley D, Vexler V L-selectin inhibition does not reduce injury in a rabbit model of transient focal cerebral ischemia. Neurol Res 2001, 23:72-78.
30. Bednar MM, Gross CE, Russell SR, Fuller SP, Ellenberger CL, Schindler E, et al. Humanized anti-L-selectin monoclonal antibody DREG200 therapy in acute thromboembolic stroke. Neurol Res 1998, 20:403-408.
31. Connolly ES, Winfree CJ, Prestigiacomo CJ, Kim SC, Choudhri TF, Hoh BL, et al. Exacerbation of cerebral injury in mice that express the P-selectin gene: identification of P-selectin blockade as a new target for the treatment of stroke. Circ Res 1997, 81:304-310.
32. Goussev AV, Zhang Z, Anderson DC, Chopp M P-selectin antibody reduces hemorrhage and infarct volume resulting from MCA occlusion in the rat. J Neurol Sci 1998, 161:16-22.
33. Huang J, Choudhri TF, Winfree CJ, McTaggart RA, Kiss S, Mocco J, et al. Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke. Stroke 2000, 31:3047-3053.
34. Mocco J, Choudhri T, Huang J, Harfeldt E, Efros L, Klingbeil C, et al. HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ Res 2002, 91:907-914.
35. Morikawa E, Zhang SM, Seko Y, Toyoda T, Kirino T Treatment of focal cerebral ischemia with synthetic oligopeptide corresponding to lectin domain of selectin. Stroke 1996, 27:951-955.
36. Takeda H, Spatz M, Ruetzler C, McCarron R, Becker K, Hallenbeck J Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke 2002, 33:2156-2163.
37. Chen Y, Ruetzler C, Pandipati S, Spatz M, McCarron RM, Becker K, et al. Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc Natl Acad Sci USA 2003, 100:15107-15112.
38. Kitagawa K, Matsumoto M, Mabuchi T, Yagita Y, Ohtsuki T, Hori M, et al. Deficiency of intercellular adhesion molecule 1 attenuates microcirculatory disturbance and infarction size in focal cerebral ischemia. J Cereb Blood Flow Metab 1998, 18:1336-1345.
39. Bowes MP, Rothlein R, Fagan SC, Zivin JA Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology 1995, 45:815-819.
40. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 2001, 57:1428-1434. Enlimomab Acute Stroke Trial Investigators.
41. Soriano SG, Coxon A, Wang YF, Frosch MP, Lipton SA, Hickey PR, et al. Mice deficient in Mac-1 (CD11b/CD18) are less susceptible to cerebral ischemia/reperfusion injury. Stroke 1999, 30:134-139.
42. Bednar MM, Wright SD, Raymond-Russell SJ, Kohut JJ, Gross CE IB4, a monoclonal antibody against the CD18 leukocyte adhesion protein, reduces intracranial pressure following thromboembolic stroke in the rabbit. Neurol Res 1996, 18:171-175.
43. Matsuo Y, Onodera H, Shiga Y, Nakamura M, Ninomiya M, Kihara T, et al. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effects of neutrophil depletion. Stroke 1994, 25:1469-1475.
44. Zhao H, Dong X, Wang X, Li X, Zhuang F, Stoltz JF, et al. Studies on single-cell adhesion probability between lymphocytes and endothelial cells with micropipette technique. Microvasc Res 2002, 63:218-226.
45. Prestigiacomo CJ, Kim SC, Connolly ES, Liao H, Yan SF, Pinsky DJ CD18-mediated neutrophil recruitment contributes to the pathogenesis of reperfused but not nonreperfused stroke. Stroke 1999, 30:1110-1117.
46. Zhang L, Zhang ZG, Zhang RL, Lu M, Krams M, Chopp M Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke. Stroke 2003, 34:1790-1795.
47. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003, 34:2543-2548.
48. Aghajanian A, Wittchen ES, Allingham MJ, Garrett TA, Burridge K Endothelial cell junctions and the regulation of vascular permeability and leukocyte transmigration. J Thromb Haemost 2008, 6:1453-1460.
49. Ferrarese C, Mascarucci P, Zoia C, Cavarretta R, Frigo M, Begni B, et al. Increased cytokine release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab 1999, 19:1004-1009.
50. Allan SM, Rothwell NJ Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001, 2:734-744.
51. Caso JR, Moro MA, Lorenzo P, Lizasoain I, Leza JC Involvement of IL-1beta in acute stress-induced worsening of cerebral ischaemia in rats. Eur Neuropsychopharmacol 2007, 17:600-607.
52. Yamasaki Y, Matsuura N, Shozuhara H, Onodera H, Itoyama Y, Kogure K Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke 1995, 26:676-680.
53. Boutin H, LeFeuvre RA, Horai R, Asano M, Iwakura Y, Rothwell NJ Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci 2001, 21:5528-5534.
54. Mulcahy NJ, Ross J, Rothwell NJ, Loddick SA Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol 2003, 140:471-476.
55. Amantea D, Russo R, Gliozzi M, Fratto V, Berliocchi L, Bagetta G, et al. Early upregulation of matrix metalloproteinases following reperfusion triggers neuroinflammatory mediators in brain ischemia in rat. Int Rev Neurobiol 2007, 82:149-169.
56. Acalovschi D, Wiest T, Hartmann M, Farahmi M, Mansmann U, Auffarth GU, et al. Multiple levels of regulation of the interleukin-6 system in stroke. Stroke 2003, 34:1864-1869.
57. Clark WM, Rinker LG, Lessov NS, Hazel K, Hill JK, Stenzel-Poore M, et al. Lack of interleukin-6 expression is not protective against focal central nervous system ischemia. Stroke 2000, 31:1715-1720.
58. Loddick SA, Turnbull AV, Rothwell NJ Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1998, 18:176-179.
59. Offner H, Subramanian S, Parker SM, Afentoulis ME, Vandenbark AA, Hurn PD Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab 2006, 26:654-665.
60. Gary DS, Bruce-Keller AJ, Kindy MS, Mattson MP Ischemic and excitotoxic brain injury is enhanced in mice lacking the p55 tumor necrosis factor receptor. J Cereb Blood Flow Metab 1998, 18:1283-1287.
61. Spera PA, Ellison JA, Feuerstein GZ, Barone FC IL-10 reduces rat brain injury following focal stroke. Neurosci Lett 1998, 251:189-192.
62. Vila N, Castillo J, Davalos A, Chamorro A Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000, 31:2325-2329.
63. Yan YP, Sailor KA, Lang BT, Park SW, Vemuganti R, Dempsey RJ Monocyte chemoattractant protein-1 plays a critical role in neuroblast migration after focal cerebral ischemia. J Cereb Blood Flow Metab 2007, 27:1213-1224.
64. Robin AM, Zhang ZG, Wang L, Zhang RL, Katakowski M, Zhang L, et al. Stromal cell-derived factor 1alpha mediates neural progenitor cell motility after focal cerebral ischemia. J Cereb Blood Flow Metab 2006, 26:125-134.
65. Shyu WC, Lin SZ, Yen PS, Su CY, Chen DC, Wang HJ, Li H Stromal cell-derived factor-1 alpha promotes neuroprotection, angiogenesis, and mobilization/homing of bone marrow-derived cells in stroke rats. J Pharmacol Exp Ther 2008, 324:834-849.
66. Chan PH Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 2001, 21:2-14.
67. Ishikawa M, Stokes KY, Zhang JH, Nanda A, Granger DN Cerebral microvascular responses to hypercholesterolemia: roles of NADPH oxidase and P-selectin. Circ Res 2004, 94:239-244.
68. Zhang F, Xu S, Iadecola C Time dependence of effect of nitric oxide synthase inhibition on cerebral ischemic damage. J Cereb Blood Flow Metab 1995, 15:595-601.
69. Moro MA, Cárdenas A, Hurtado O, Leza JC, Lizasoain I Role of nitric oxide after brain ischaemia. Cell Calcium 2004, 36:265-275.
70. Pruss H, Prass K, Ghaeni L, Milosevic M, Muselmann C, Freyer D, et al. Inducible nitric oxide synthase does not mediate brain damage after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2008, 28:526-539.
71. Marsh BJ, Williams-Karnesky RL, Stenzel-Poore MP Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 2009, 158:1007-1020.
72. Caso JR, Pradillo JM, Hurtado O, Lorenzo P, Moro MA, Lizasoain I Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007, 115:1599-1608.
73. Lehnardt S, Lehmann S, Kaul D, Tschimmel K, Hoffmann O, Cho S, et al. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol 2007, 190:28-33.
74. Tasaki K, Ruetzler CA, Ohtsuki T, Martin D, Nawashiro H, Hallenbeck JM Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats. Brain Res 1997, 748:267-270.
75. Stevens SL, Ciesielski TMP, Marsh BJ, Yang T, Homen DS, Boule J, et al. Toll-like receptor 9: a new target of ischemic preconditioning in the brain. J Cereb Blood Flow Metab 2008, 28:1040-1047.
76. Hua F, Ma J, Ha T, Kelley J, Williams DL, Kao RL, et al. Preconditioning with a TLR2 specific ligand increases resistance to cerebral ischemia/reperfusion injury. J Neuroimmunol 2008, 199:75-82.
77. Mori E, del Zoppo GJ, Chambers JD, Copeland BR, Arfors KE Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons. Stroke 1992, 23:712-718.
78. Yilmaz G, Granger DN Leukocyte recruitment and ischemic brain injury. Neuromol Med 2010, 12:193-204. Available from: http://dx.doi.org/10.1007/S12017-009-8074-1.
79. Tailor A, Cooper D, Granger DN Platelet-vessel wall interactions in the microcirculation. Microcirculation 2005, 12:275-285.
80. Massberg S, Enders G, Matos FC, Tomic LI, Leiderer R, Eisenmenger S, et al. Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood 1999, 94:3829-3838.
81. Russell J, Cooper D, Tailor A, Stokes KY, Granger DN Low venular shear rates promote leukocyte-dependent recruitment of adherent platelets. Am J Physiol Gastrointest Liver Physiol 2003, 284:G123-9.
82. Carvalho-Tavares J, Hickey MJ, Hutchison J, Michaud J, Sutcliffe IT, Kubes P A role for platelets and endothelial selectins in tumor necrosis factor-alpha-induced leukocyte recruitment in the brain microvasculature. Circ Res 2000, 87:1141-1148.
83. Salter JW, Krieglstein CF, Issekutz AC, Granger DN Platelets modulate ischemia/reperfusion-induced leukocyte recruitment in the mesenteric circulation. Am J Physiol Gastrointest Liver Physiol 2001, 281:G1432-9.
84. Suzuki K, Sugimura K, Hasegawa K, Yoshida K, Suzuki A, Ishizuka K, et al. Activated platelets in ulcerative colitis enhance the production of reactive oxygen species by polymorphonuclear leukocytes. Scand J Gastroenterol 2001, 36:1301-1306.
85. Ritter LS, Stempel KM, Coull BM, McDonagh PF Leukocyte-platelet aggregates in rat peripheral blood after ischemic stroke and reperfusion. Biol Res Nurs 2005, 6:281-288.
86. Gavins F, Yilmaz G, Granger DN The evolving paradigm for blood cell-endothelial cell interactions in the cerebral microcirculation. Microcirculation 2007, 14:667-681.
87. Brouns R, De Deyn PP The complexity of neurobiological processes in acute ischemic stroke. Clin Neurol Neurosurg 2009, 111:483-495.
88. Huang ZG, Xue D, Preston E, Karbalai H, Buchan AM Biphasic opening of the blood-brain barrier following transient focal ischemia: effects of hypothermia. Can J Neurol Sci 1999, 26:298-304.
89. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003, 107:598-603.
90. Rosell A, Cuadrado E, Ortega-Aznar A, Hernández-Guillamon M, Lo EH, Montaner J MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008, 39:1121-1126.
91. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
92. Borén J, Gustafsson M, Skålén K, Flood C, Innerarity TL Role of extracellular retention of low density lipoproteins in atherosclerosis. Curr Opin Lipidol 2000, 11:451-456.
93. Cai H NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ Res 2005, 96:818-822.
94. Saha P, Modarai B, Humphries J, Mattock K, Waltham M, Burnand KG, et al. The monocyte/macrophage as a therapeutic target in atherosclerosis. Curr Opin Pharmacol 2009, 9:109-118.
95. Weber C, Zernecke A, Libby P The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008, 8:802-815.
96. Hansson GK Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009, 7(Suppl. 1):328-331.
97. Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Bidzhekov K, Meiler S, et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 2008, 102:209-217.
98. Larionov S, Dedeck O, Birkenmeier G, Thal DR Expression of alpha2-macroglobulin, neutrophil elastase, and interleukin-1alpha differs in early-stage and late-stage atherosclerotic lesions in the arteries of the circle of Willis. Acta Neuropathol 2007, 113:33-43.
99. -/- mice. Arterioscler Thromb Vasc Biol 2008, 28:84-89.
100. Bot I, de Jager SC, Zernecke A, Lindstedt KA, van Berkel TJ, Weber C, et al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation 2007, 115:2516-2525.
101. Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P, et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 2007, 13:719-724.
102. Tiwari RL, Singh V, Barthwal MK Macrophages: an elusive yet emerging therapeutic target of atherosclerosis. Med Res Rev 2008, 28:483-544.
103. Bui QT, Prempeh M, Wilensky RL Atherosclerotic plaque development. Int J Biochem Cell Biol 2009, 41:2109-2113.
104. Tardif J, McMurray JJV, Klug E, Small R, Schumi J, Choi J, et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:1761-1768.
105. Viles-Gonzalez JF, Fuster V, Corti R, Valdiviezo C, Hutter R, Corda S, et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition-a magnetic resonance imaging study. Eur Heart J 2005, 26:1557-1561.
106. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007, 115:1634-1642.
107. Taleb S, Tedgui A, Mallat Z Regulatory T-cell immunity and its relevance to atherosclerosis. J Intern Med 2008, 263:489-499.
108. Hansson GK, Libby P The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6:508-519.
109. Huber SA, Sakkinen P, David C, Newell MK, Tracy RP T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation 2001, 103:2610-2616.
110. Veillard NR, Steffens S, Burger F, Pelli G, Mach F Differential expression patterns of proinflammatory and antiinflammatory mediators during atherogenesis in mice. Arterioscler Thromb Vasc Biol 2004, 24:2339-2344.
111. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AL, Gourdy P, Zoll J, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006, 12:178-180.
112. Badimon L, Vilahur G Platelets, arterial thrombosis and cerebral ischemia. Cerebrovasc Dis 2007, 24(Suppl. 1):30-39.
113. Gleissner CA, von Hundelshausen P, Ley K Platelet chemokines in vascular disease. Arterioscler Thromb Vasc Biol 2008, 28:1920-1927.
114. Viles-Gonzalez JF, Fuster V, Badimon JJ Links between inflammation and thrombogenicity in atherosclerosis. Curr Mol Med 2006, 6:489-499.
115. Doran AC, Meller N, McNamara CA Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2008, 28:812-819.
116. Nilsson J, Fredrikson GN, Bjorkbacka H, Chyu KY, Shah PK Vaccines modulating lipoprotein autoimmunity as a possible future therapy for cardiovascular disease. J Intern Med 2009, 266:221-231.
117. Binder CJ, Chang M, Shaw PX, Miller YI, Hartvigsen K, Dewan A, et al. Innate and acquired immunity in atherogenesis. Nat Med 2002, 8:1218-1226.
118. Chyu K, Zhao X, Reyes OS, Babbidge SM, Dimayuga PC, Yano J, et al. Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice. Biochem Biophys Res Commun 2005, 338(4):1982-1989.
119. van Puijvelde GHM, van Es T, van Wanrooij EJA, Habets KLL, de Vos P, van der Zee R, et al. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:2677-2683.
120. Esmon CT Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev 2009, 23:225-229.
121. Masuhr F, Mehraein S, Einhäupl K Cerebral venous and sinus thrombosis. J Neurol 2004, 251:11-23.
122. Aird WC Vascular bed-specific thrombosis. J Thromb Haemost 2007, 5(Suppl. 1):283-291.
123. Ferro JM, Canhão P, Stam J, Bousser M, Barinagarrementeria F Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004, 35:664-670.
124. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003, 197:1585-1598.
125. Myers DD, Rectenwald JE, Bedard PW, Kaila N, Shaw GD, Schaub RG, et al. Decreased venous thrombosis with an oral inhibitor of P selectin. J Vasc Surg 2005, 42:329-336.
126. Ramacciotti E, Hawley AE, Farris DM, Ballard NE, Wrobleski SK, Myers DD, et al. Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis. Thromb Haemost 2009, 101:748-754.
127. Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005, 105:192-198.
128. Nagai M, Yilmaz CE, Kirchhofer D, Esmon CT, Mackman N, Granger DN Role of coagulation factors in cerebral venous sinus and cerebral microvascular thrombosis. Neurosurgery 2010, 66:560-566.
129. Bernardo A, Ball C, Nolasco L, Choi H, Moake JL, Dong JF Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost 2005, 3:562-570.
130. Lopez JA, Chen J Pathophysiology of venous thrombosis. Thromb Res 2009, 123(Suppl. 4):S30-4.
131. Eriksson EE, Karlof E, Lundmark K, Rotzius P, Hedin U, Xie X Powerful inflammatory properties of large vein endothelium in vivo. Arterioscler Thromb Vasc Biol 2005, 25:723-728.
132. Stam J Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005, 352:1791-1798.
133. Yoshikawa T, Abe O, Tsuchiya K, Okubo T, Tobe K, Masumoto T, et al. Diffusion-weighted magnetic resonance imaging of dural sinus thrombosis. Neuroradiology 2002, 44:481-488.
134. Nagai M, Terao S, Yilmaz G, Yilmaz CE, Esmon CT, Watanabe E, et al. Roles of inflammation and the activated protein C pathway in the brain edema associated with cerebral venous sinus thrombosis. Stroke 2010, 41:147-152.